Allergimmuno Diagnostics Profile
Key Indicators
- Authorised Capital ₹ 1.00 M
as on 28-06-2024
- Paid Up Capital ₹ 0.50 M
as on 28-06-2024
- Company Age 11 Year, 5 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 0.80 M
as on 28-06-2024
- Revenue 54.94%
(FY 2022)
- Profit 22.05%
(FY 2022)
- Ebitda 15.18%
(FY 2022)
- Net Worth 22.32%
(FY 2022)
- Total Assets 42.37%
(FY 2022)
About Allergimmuno Diagnostics
The Company is engaged in the Healthcare Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 1.00 M and a paid-up capital of Rs 0.50 M.
The company currently has active open charges totaling ₹0.80 M.
Pratanu Biswas, Rajorshi Chakraborty, and Vivek Agarwal serve as directors at the Company.
- CIN/LLPIN
U74900WB2013PTC195022
- Company No.
195022
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
25 Jun 2013
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Kolkata
Industry
Company Details
- Location
Kolkata, West Bengal, India
- Telephone
- Email Address
- Website
- Social Media
Who are the key members and board of directors at Allergimmuno Diagnostics?
Board Members(3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Rajorshi Chakraborty  | Director | 25-Jun-2013 | Current |
| Pratanu Biswas | Director | 04-Jun-2021 | Current |
| Vivek Agarwal | Director | 29-Mar-2019 | Current |
Financial Performance of Allergimmuno Diagnostics.
Allergimmuno Diagnostics Private Limited, for the financial year ended 2022, experienced significant growth in revenue, with a 54.94% increase. The company also saw a substantial improvement in profitability, with a 22.05% increase in profit. The company's net worth Soared by an impressive increase of 22.32%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Allergimmuno Diagnostics?
In 2019, Allergimmuno Diagnostics had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Hdfc Bank Limited Creation Date: 17 Mar 2023 | ₹0.80 M | Open |
How Many Employees Work at Allergimmuno Diagnostics?
Allergimmuno Diagnostics has a workforce of 25 employees as of Apr 06, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Allergimmuno Diagnostics, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Allergimmuno Diagnostics's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
